

Amendments to the Claims

Please amend the claims as follows:

[Claims 1-66 (Cancelled).]

67. (Original) A monoclonal antibody which specifically binds to APRIL polypeptide and blocks binding of said APRIL polypeptide to a TACI receptor or a BCMA receptor.

68. (Original) The monoclonal antibody of claim 67 which further blocks binding of said APRIL polypeptide to a TACI receptor and a BCMA receptor.

69 (Original) The monoclonal antibody of claim 67 wherein said monoclonal antibody comprises the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

70. (Original) A monoclonal antibody which binds to the same epitope as the epitope to which the 3C6.4.2 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1347 binds.

71 (Original) The hybridoma cell line which produces monoclonal antibody 3C6.4.2 and deposited with ATCC as accession number PTA-1347.

72. (Original) The monoclonal antibody 5E11.1.2 secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

73. (Original) A monoclonal antibody which binds to the same epitope as the epitope to which the 5E11.1.2 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1346 binds.

74. (Original) The hybridoma cell line which produces monoclonal antibody 5E11.1.2 and deposited with ATCC as accession number PTA-1346.

75. (Original) The monoclonal antibody 5G8.2.2 secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

76. (Original) A monoclonal antibody which binds to the same epitope as the epitope to which the 5G8.2.2 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1345 binds.

77. (Original) The hybridoma cell line which produces monoclonal antibody 5G8.2.2 and deposited with ATCC as accession number PTA-1345.

78. (Original) The monoclonal antibody 5E8.7.4 secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

79. (Original) A monoclonal antibody which binds to the same epitope as the epitope to which the 5E8.7.4 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1344 binds.

80. (Original) The hybridoma cell line which produces monoclonal antibody 5E8.7.4 and deposited with ATCC as accession number PTA-1344.

81. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

82. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E11.1.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

83. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5G8.2.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

84. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E8.7.4 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

85. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

86. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E11.1.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

87. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5G8.2.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

88. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E8.7.4 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

89. (New) A composition comprising the monoclonal antibody according to any one of claims 67-70, 72-73, 75-76 and 78-79 and a carrier.

90. (New) A composition comprising the chimeric anti-APRIL antibody according to any one of claims 81-84 and a carrier.

91. (New) A composition comprising the humanized anti-APRIL antibody according to any one of claims 85-88 and a carrier.

92. (New) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the monoclonal antibody according to any one of claims 67-70, 72-73 and 78-79.

93. (New) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the chimeric anti-APRIL antibody according to any one of claims 81, 82 and 84.

94. (New) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the humanized antibody according to any one of claims 85, 86 and 88.